T. Rowe Price Investment Management
TEVA icon

T. Rowe Price Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

T. Rowe Price Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,468
Closed -$30K – 952
2025
Q3 		$30K Sell
1,468
-831
-36% -$14.6K ﹤0.01% 669
2025
Q2 		$39K Buy
+2,299
New +$37.1K ﹤0.01% 665

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

T. Rowe Price Investment Management's TEVA Position: Q4 2025 in Review

T. Rowe Price Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 1,468 shares — an estimated $30K sold.

T. Rowe Price Investment Management first reported a position in TEVA in Q2 2025 and held it in 2 quarters. The position peaked at $39K in Q2 2025. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • T. Rowe Price Investment Management reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 1,468 Teva Pharmaceuticals shares in Q4 2025, an estimated $30K.
  • T. Rowe Price Investment Management first reported a position in Teva Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • T. Rowe Price Investment Management's Teva Pharmaceuticals position peaked at $39K in Q2 2025.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.